NIAID

December 10, 2020

Exploiting viral vulnerabilities

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

By Bill Snyder
C. Henrique Serezani, PhD, right, and colleagues, from left, Amondrea Blackman, Nathan Klopfenstein and Júlia Miranda Ribeiro Bazzano are studying the early events of the inflammatory response to infection.
December 10, 2020

Study details early events of inflammatory response

Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.

By Leigh MacMillan
November 2, 2020

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

By Bill Snyder
bacteria microbiome
October 20, 2020

Preserving gut mucus architecture

A new method that keeps microbes and gut cells together will be useful for studies of complex host-microbe interactions and for analysis of clinical specimens.

By Leigh MacMillan
October 6, 2020

Early steps in reovirus replication

Conformational change in a reovirus surface protein modulate the virus’s attachment to host cells, Vanderbilt researchers have found.

By Leigh MacMillan
September 22, 2020

Rational vaccine design

Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.

By Leigh MacMillan
September 17, 2020

Probing pathogen antibiotic resistance

Understanding how bacteria evolve resistance to antibiotics and host stresses could guide the development of more effective antimicrobial therapeutics.
By Leigh MacMillan
August 11, 2020

Risk marker for repeat sinus surgery

An inflammatory factor in mucus could be a biomarker of treatment-resistant chronic sinusitis used to determine which patients are at risk for repeat sinus surgery.
By Leigh MacMillan
August 6, 2020

The importance of estrogen cycles

Deborah Lannigan and colleagues identify a key regulator of the estrogen receptor and suggest that its downregulation by oral contraceptives may increase oxidative stress and DNA damage, a common cause of cancer.
By Sarah E. Glass
July 23, 2020

Stomach bug hit-and-run

The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.
By Leigh MacMillan
July 23, 2020

Cellular antiviral defenses

A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
By Leigh MacMillan
July 15, 2020

Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
By Bill Snyder
July 15, 2020

Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
By Bill Snyder
1 2 3 4 5 6 … 15